
usd feb pm et
summari lead biotech compani major treatment anemia neutropenia
rheumatoid psoriat arthriti psoriasi cancer osteoporosi
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
anticip sale growth
billion larg due amgn
acquisit drug otezla amgn legaci
product face well-known headwind
off-set near-term growth newer product
aimovig prolia xgeva kyproli
august litig
sandoz concern drug enbrel made
amgn product sale deter
aspir enbrel biosimilar manufactur
navig biosimilar competit
brand drug long time
build biosimilar busi
recent launch first ever biosimilar
 kanjin refer herceptin
expect oper margin
spend heavili advanc pipelin
support recent acquir otezla
busi support expans key
market china japan biosimilar
near term expect priorit
capit spend pipelin expans
develop long-term revenu growth
think share trade
ep near fair valu
sale matur drug declin
growth new product ramp expect
biosimilar crucial growth driver
long run particularli given
recent launch believ
biosimilar busi could worth
billion annual sale also
mani early-stag oncolog program
promis drug develop program
address kra mutat
mutat previous thought
undrugg occur mani cancer
lung adenocarcinoma
program progress rapidli like
key catalyst stock movement
risk recommend target
includ pipelin failur inabl obtain new
develop difficulti obtain
reimburs third-parti payer
target reflect
forward price-to-earnings multipl
ep estim
forward price-to-earnings ratio rang
past three year
risk assess reflect particip
highli competit regul market subject
chang govern reimburs polici
drug safeti oversight see risk mitig
diversifi product roster gener robust
cash flow support share repurchas cash dividend
new asset acquisit
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
oper
corpor overview amgen inc one largest biotechnolog compani world
compani commit unlock potenti biolog patient suffer seriou ill
discov develop manufactur deliv innov human therapeut approach
begin use tool like advanc human genet unravel complex diseas understand
fundament human biolog
compani product sale three major wholesal -- cardin
-- account total revenu year end decemb
combin basi wholesal account amgn gross product sale
year end decemb respect
world-wide gross revenu year
billion product sale gener largest contributor drug
enbrel neulasta prolia aranesp xgeva sensipar/mimpara
sale gener februari least phase drug
develop program phase ii program phase program
competit environ oper highli competit environ number
market product indic diseas area product treatment current
avail pursu amgn competitor research develop activ
addit competitor-market product target genet pathway amgn recent
launch market product pursu current competit could impact price
market share product continu pursu way increas valu medicin
innov life cycl includ expand diseas area
amgn product indic find new method make deliveri amgn medicin easier
less costli activ offer import opportun differenti
certain exist patent amgn princip product expir compani face new
increas competit includ biosimilar gener may also compet
biosimilar gener version competitor product biosimilar anoth version biolog
product market approv sought obtain base demonstr
highli similar origin refer product believ advers impact amgn product
sale biosimilar competit like brand biolog competit seen
brand small molecul face gener although expect biosimilar compet price mani
patient provid payer may continu place high valu reput reliabl safeti
product alreadi use decemb competitor approv
biosimilar version epogen neulasta enbrel
major develop given compani wide pipelin product portfolio compani frequent
signific develop highlight signific recent develop
august enter agreement purchas world-wide right treatment otezla
celgen celg billion cash billion net estim tax benefit otezla
oral non-biolog treatment chronic inflammatori diseas area alreadi
well-establish commerci oper enbrel amgevita august expect otezla
sale grow year-over-year approxim billion surpass billion annual
sale expir key patent februari expect transact immedi
accret close end
may announc work promis drug develop program
address kra mutat occur lung adenocarcinoma
common form non-smal cell lung cancer colon cancer low single-digit percent
cancer well mutat undrugg past year
may fda approv aimovig novel treatment develop migrain prevent aimovig
self-administ monthli devic sureclick autoinjector requir
septemb announc deal regard humira key
drug biosimilar amjevita deal grant licens humira intellectu properti
licens begin januari began octob europ
fda european commiss approv repatha treatment adult
hypercholesterolemia high cholesterol patent litig past year
regeneron sanofi regard compet hypercholesterolemia drug praluent
financi trend gener billion revenu reflect growth
year-over-year compound annual growth rate compound-annual-growth-rate compani adjust ep
grew year-over-year reflect compound-annual-growth-rate compani low level
debt net debt total capit march gener billion free
cash flow billion given compani cash flow robust balanc
sheet believ compani continu fund program market
activit forese futur
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc februari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit outlook biotechnolog
defens sub-industri expect
see ramp-up new drug sale continu
develop mani new innov therapi
declin preval patent
expir anticip
novel fda drug approv
year-over-year record level
partli due govern shutdown earli
year fda approv novel drug
shatter previou record sinc
novel approv set new
drug typic take least five year
reach peak sale level mean
overal biotech industri like see
promis sale growth next year
addit think mani drug
either newli approv late-stag
clinic trial repres major advanc
treatment technolog gene therapi
zolgensma believ cure spinal
muscular atrophi one inject
although deal count
biopharmaceut lower
past decad total deal valu
transact anticip largest
amount sinc accord
evaluatepharma total deal valu driven
coupl mega-d bristol-mey
squibb acquisit celgen
abbvi acquisit botox
manufactur allergan decemb
biotech industri debt level valuat
remain low rel histor level
rel industri lead us
believ continu
favor environ howev
think difficult beat total
deal valu transact
investor interest
biotechnolog stock mute high
drug price intens scrutini
 polit apparatu despit polit
littl happen regulatori
legisl front neg impact
profit biotech firm believ
littl continu achiev politician
address rise health care cost
especi around drug price
impeach proceed novemb
presidenti candid may continu bring
drug price key issu anticip
stock near term think
legisl initi relat drug fall
focu howev presidenti
elect expect drug legisl becom
key area focu legisl
exclus period origin biolog
drug face competit form
biosimilar also typic
manufactur biopharmaceut firm
howev brand biolog manufactur
aggress use patent law
commerci leverag delay
commerci biosimilar
brand biolog maintain market
domin longer result bar
radic regulatori legisl chang
expect biosimilar continu advanc
slowli next sever year
increas driven ralli
compar rise valu
 composit index
declin
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
protect exclus decis preclud
futur aspir enbrel biosimilar manufactur contest enbrel
patent think recent decis signific deterr
litig overhang remov lift price target share
base forward price-to-earnings ratio ep estim
et cfra keep hold opinion share amgen inc
maintain target base
averag forward price-to-earnings ep estim ep
vs beat consensu estim take ep
ep sale
declin billion driven increas competit due patent
expir repurchas billion worth share
expect lift share repurchas billion
promis kra inhibitor continu focal point
like import valuat program progress
rapidli complet enrol monotherapi expans cohort
enrol non-smal cell lung cancer patient combin
arm sandoz litig best-sel enbrel continu
overhang share opinion especi sinc decis expect soon
analyst research note compani news
et cfra keep hold opinion share amgen inc
lift target price reflect forward price-to-earnings
multipl vs amgn averag
ep estim ep vs exceed consensu
estim howev provid underwhelm outlook
adjust ep believ conserv keep
ep estim initi ep total
revenu declin billion sale amgn legaci product
face continu eros due biosimilar gener competit sale key
product mostli in-lin expect amgn nascent biosimilar
portfolio perform ahead expect sale million
although due inventori stock expect
investor focu remain critic data readout lung cancer
tezepelumab asthma omecamtiv heart failur otezla
et cfra keep hold opinion share amgen inc
keep target price reflect forward price-to-earnings multipl
vs averag ep estim
ep vs beat consensu estim
rais ep ep
expect anticip acquisit otezla drug immedi
contribut revenu margin growth total revenu declin
billion reflect continu impact biosimilar gener competit
key product product perform mix overal top
bottom line growth exceed expect repurchas billion
worth share quarter bring total valu share repurchas
far billion anticip key catalyst
expect clinic updat phase
trial result tezepelumab asthma late /kevin huang cfa
et cfra keep buy opinion share
share trade sharpli today news patent
trial appeal board ptab review claim relat three patent
key drug soliri compris product revenu
previous highlight signific revenu concentr soliri
signific risk neg outcom ptab review could expos
soliri biosimilar competit howev
alreadi expect soliri sale could face competit pressur
view success execut strategi mitig
competit pressur strategi primarili involv convert soliri
patient newer conveni drug ultomiri expect
ptab review take year /kevin huang cfa
pm et cfra maintain hold opinion share inc
today enter agreement purchas world-wide
right treatment otezla celgen celg billion
cash billion net estim tax benefit otezla oral
non-biolog treatment chronic inflammatori diseas area
alreadi well-establish commerci oper enbrel amgevita
expect otezla sale grow year-over-year approxim
billion surpass billion annual sale expir
key patent februari price paid otezla higher
initi expect celg get think one
best-posit compani capit opportun addit
expect achiev least low double-digit growth
expect label expans increas market penetr expect
transact immedi accret close end
et cfra reiter hold opinion share amgen inc
share trade recent august
announc court rule favor valid two
patent relat key drug enbrel sale decis
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
